Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.60 |
| ▸ | PRKX | P51817 | 1/20 | 0.60 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.60 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135151 | 0.88 | MRGPRX4 (0.53) | S1PR1PRKXACVR1S1PR5MEN1 | |
| SCHEMBL16355760 | 0.87 | S1PR1 (0.57) | S1PR1PRKXACVR1S1PR5MEN1 | |
| SCHEMBL15486663 | 0.87 | S1PR1 (0.54) | S1PR1PRKXACVR1S1PR5MEN1 | |
| SCHEMBL15876231 | 0.86 | FFAR1 (0.62) | S1PR1PRKXACVR1S1PR5FFAR1 | |
| SCHEMBL3813849 | 0.84 | PTGER1 (0.54) | MEN1KMT2ASMN1; SMN2ALDH1A1MAOB | |
| SCHEMBL695003 | 0.83 | S1PR1 (0.57) | S1PR1PRKXACVR1S1PR5MEN1 | |
| SCHEMBL16355724 | 0.83 | S1PR1 (0.57) | S1PR1PRKXACVR1S1PR5MEN1 | |
| SCHEMBL13195438 | 0.83 | S1PR1 (0.53) | S1PR1PRKXACVR1S1PR5MEN1 | |
| SCHEMBL21382927 | 0.82 | NR4A2 (0.54) | MEN1KMT2ASMN1; SMN2ALDH1A1MAOB | |
| SCHEMBL4840328 | 0.82 | FFAR1 (0.54) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780337-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-2780337-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-2693882-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2693882-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2757093-B1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-9199927-B2 | Guanidinobenzoic acid compound | ASTELLAS PHARMA INC. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9018224-B2 | Substituted cyclopropyl compounds useful as GPR119 agonists | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018224-B2 | Substituted cyclopropyl compounds useful as GPR119 agonists | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018224-B2 | Substituted cyclopropyl compounds useful as GPR119 agonists | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-8957062-B2 | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2015-02-17 | — | — | US | disclosed |
| EP-2780337-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | Merck Sharp & Dohme Corp. (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2757093-A1 | GUANIDINOBENZOIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-20140057893-A1 | SUBSTITUTED CYCLOPROPLY COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057893-A1 | SUBSTITUTED CYCLOPROPLY COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057893-A1 | SUBSTITUTED CYCLOPROPLY COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2693882-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck Sharp & Dohme Corp. (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2013074388-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013074388-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2012138845-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012138845-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057893-A1 | SUBSTITUTED CYCLOPROPLY COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR139, GPR27 | S1PR1 397/4885PRKX 1015/4885ACVR1 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.